Galera Therapeutics and Biossil Join Forces for Cancer Treatment
Galera Therapeutics has recently solidified an agreement with Toronto-based Biossil, focusing on advancing the development of its dismutase mimetics portfolio. This collaboration includes the acquisition of avasopasem and rucosopasem formulations aimed at improving cancer treatment.
The asset purchase agreement, which amounts to an initial payment of $3.5 million, also outlines further potential payments tied to regulatory and commercial milestones, summing up to $105 million. Under this agreement, Biossil will take over responsibilities to Blackstone Life Sciences related to these products, including a 4% royalty if either agent reaches the market.
Advancements in Cancer Treatment
Galera Therapeutics continues to prioritize its lead program, a pan-inhibitor targeting Nitric Oxide Synthase (NOS), which is currently undergoing a multicenter Phase 2 trial. This trial is particularly significant as it focuses on metaplastic breast cancer and explores the efficacy of combining this treatment with alpelisib and nab-paclitaxel.
As part of this trial, Galera has implemented a lead-in phase designed to optimize alpelisib dosing in collaboration with Houston Methodist, with plans to expand enrolment to additional prestigious sites, including the University of Texas MD Anderson Cancer Center and the National Institute of Health Clinical Center.
Results from Clinical Trials
The clinical outcomes from trials involving avasopasem have shown promise. In a randomized double-blind Phase 3 trial encompassing 407 patients, avasopasem demonstrated a notable reduction in the incidence of severe oral mucositis (SOM) among those undergoing standard chemoradiotherapy for head and neck cancer. This outcome, statistically significant with a p-value of 0.045, reflects a 16% relative reduction in cases of SOM and a 56% reduction in duration with a p-value of 0.002.
These results are expected to be published in upcoming editions of eClinical Medicine and have already garnered attention within the medical community. Furthermore, the FDA has recognized avasopasem by granting it Fast Track and Breakthrough Therapy designations, highlighting its potential in alleviating SOM caused by radiotherapy.
The Role of Dismutase Mimetics
Dismutase mimetics, such as avasopasem, have drawn attention due to their promising role in cancer therapeutics, particularly showcased in preclinical studies. Galera has undertaken initiatives exploring the combination of avasopasem with advanced stereotactic body radiotherapy (SBRT) for patients battling locally advanced pancreatic cancer.
Dr. Mel Sorensen, President & CEO of Galera, expressed his enthusiasm regarding the agreement, stating that it substantially boosts the prospects for bringing avasopasem to patients in need. He emphasized that Biossil's expertise and resources are vital for navigating the clinical and regulatory phases that lie ahead.
Complementing Sorensen's comments, Dr. Alexander Mosa, Chief Scientific Officer at Biossil, acknowledged the urgency for effective treatments that reduce the adverse effects of chemoradiotherapy, committing to advancing avasopasem diligently.
About Galera Therapeutics
Galera Therapeutics, Inc. remains dedicated to advancing innovative solutions for patients with challenging forms of advanced breast cancer. Historically, the company has emphasized the development of avasopasem as a small molecule intended to mitigate the toxicities associated with conventional treatment regimens.
About Biossil
Biossil is recognized for its forward-thinking approach as an AI-native drug development company, dedicated to pioneering new, first-in-class therapies for life-threatening disorders. It operates from Toronto and Boston, collaborating with leading medical institutions and leveraging cutting-edge AI technology to revitalize promising therapeutic approaches.
Frequently Asked Questions
What is the purpose of the agreement between Galera and Biossil?
The agreement aims to advance the development of Galera's dismutase mimetics portfolio, specifically avasopasem and rucosopasem, enhancing cancer treatment options.
What are dismutase mimetics?
Dismutase mimetics are innovative therapeutics that mimic the action of natural enzymes to reduce oxidative stress, with potential applications in cancer treatment.
How does avasopasem affect severe oral mucositis?
Avasopasem has shown significant efficacy in reducing the incidence and duration of severe oral mucositis in patients undergoing chemotherapy and radiation, improving their overall treatment experience.
What designations has the FDA granted to avasopasem?
The FDA has granted avasopasem Fast Track and Breakthrough Therapy designations, facilitating its clinical development and regulatory review.
Why is Galera's lead program important?
Galera's lead program, a pan-NOS inhibitor, targets the hardest-to-treat forms of advanced breast cancer, showcasing the company’s commitment to developing vital cancer therapies.
